STOCK TITAN

AKTIS ONCOLOGY INC Stock Price, News & Analysis

AKTS Nasdaq

Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.

Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.

News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.

Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.

Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.

For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.

Rhea-AI Summary

Akoustis Technologies has appointed Ken Boller as its new Chief Financial Officer, effective immediately. Boller, who joined Akoustis in 2017 and has served as Interim CFO since 2018, brings over 25 years of finance experience to the role. He is committed to cost control and capital allocation to support sales growth and capacity expansion. The company is actively ramping production of its Wi-Fi 6 and 5G XBAW™ filter solutions and plans to increase annual production capacity to approximately 500 million filters. This leadership change aims to strengthen Akoustis amidst rapid market growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
management
-
Rhea-AI Summary

Akoustis Technologies (NASDAQ: AKTS) announced five new Wi-Fi design wins, including four using Wi-Fi 6E and one using Wi-Fi 6 XBAW™ filters. These wins are expected to ramp into production and ship in 2022, increasing Akoustis' total design wins in Wi-Fi to 13. The company has also expanded its production capacity, targeting approximately 500 million filters annually at its New York facility. CEO Jeff Shealy highlighted continued momentum in the Wi-Fi segment due to performance advantages over competitors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.8%
Tags
none
-
Rhea-AI Summary

Akoustis Technologies (AKTS) reports a record revenue of $3.7 million for Q2 FY22, marking a 96% sequential increase. The company expects over 25% growth in the current quarter, driven by strong demand for its patented XBAW™ RF filter solutions across 5G and Wi-Fi markets. Five new design wins in Wi-Fi were announced, alongside a significant purchase order from a tier-1 5G mobile customer. As of December 31, 2021, Akoustis holds $67.5 million in cash. Despite ongoing challenges from COVID and semiconductor shortages, management forecasts continued growth due to a robust sales pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.8%
Tags
Rhea-AI Summary

Akoustis Technologies, Inc. (NASDAQ: AKTS) will webcast its Q2FY22 results on January 31, 2022, at 8:00 am ET. The event includes a Q&A session. To participate by phone, call 877-407-3982 (domestic) or 201-493-6780 (international). The webcast will be available on the Company’s website. Akoustis is ramping up production, targeting an output of 500 million filters per year to meet increasing demand for 5G, Wi-Fi 6, and Wi-Fi 6E technologies.

The company is expanding its product lines in these areas, leveraging its cutting-edge XBAW™ technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
conferences
-
Rhea-AI Summary

Akoustis Technologies (NASDAQ: AKTS) announced that senior management will present at the 24th Annual Needham Growth Conference on January 10, 2022, at 2:45 PM ET. The conference will be held virtually due to COVID-19 precautions. Investors can access the presentation via the company's investor website. Akoustis is ramping production capacity at its New York facility to 500 million filters per year to meet growing demand for its 5G and WiFi 6E solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
conferences
-
Rhea-AI Summary

Akoustis Technologies, Inc. (NASDAQ: AKTS) announced a purchase order from a new tier-1 module maker for the development of a 5G mobile XBAW filter. Initial samples are expected in the first half of CY22, with production ramp targeted for the second half of CY23. This collaboration marks the fourth active customer engagement for Akoustis' XBAW technology. The company aims to increase its annual production capacity to approximately 500 million filters, responding to growing demand in the 5G and WiFi markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
Rhea-AI Summary

Akoustis Technologies, Inc. (NASDAQ: AKTS) will present at the 2nd Annual Oppenheimer 5G Summit on December 14, 2021, at 9:05 am ET. Due to COVID-19 precautions, the event will be virtual. The presentation will be available on the investor website. Akoustis is ramping up production of its WiFi 6 and 5G filter solutions, targeting an annual capacity of approximately 500 million filters by the end of 2021. The company is actively engaged with customers to meet the growing demand for advanced RF filter technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.99%
Tags
conferences
-
Rhea-AI Summary

Akoustis Technologies (NASDAQ: AKTS) announced that CEO Jeff Shealy will appear on TD Ameritrade Network today at 11:20 AM ET. The company is ramping up production of its WiFi 6 and 5G filter solutions, expecting to increase capacity at its New York facility to 500 million filters annually by the end of 2021. Akoustis aims to capture a share of the growing RF filter market with its proprietary XBAW™ technology, enhancing performance and bandwidth. The company is actively engaged with customers for expected sales growth in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
none
-
Rhea-AI Summary

Akoustis Technologies, Inc. (NASDAQ: AKTS) announced that Dave Aichele, EVP of Business Development, will present on "RF Acoustic Filters for High-Performance Wi-Fi" at the Wi-Fi Now Conference on November 17, 2021, at 1:25 PM ET. This virtual event is part of Akoustis's initiatives to enhance its Wi-Fi 6 and 5G filter solutions. The company plans to boost annual production capacity at its New York facility to 500 million filters by the end of 2021, addressing an increasing demand in the RF filter market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
conferences
Rhea-AI Summary

Akoustis Technologies announced its fourth design win for patented WiFi 6E XBAW filters, set to be integrated into a new carrier-grade WiFi 6E gateway by a WiFi OEM. The solution will use 5.5 GHz and 6.5 GHz tandem filter modules for a 2X2 MU-MIMO carrier gateway product, with production expected to ramp up in the first half of 2022. This expansion aligns with the growing demand for high-performance coexistence filters following the FCC's approval of the 5.9 to 7.1 GHz bands for unlicensed use.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
none

FAQ

What is the current stock price of AKTIS ONCOLOGY (AKTS)?

The current stock price of AKTIS ONCOLOGY (AKTS) is $18.64 as of March 25, 2026.

What is the market cap of AKTIS ONCOLOGY (AKTS)?

The market cap of AKTIS ONCOLOGY (AKTS) is approximately 1.0B.

AKTS Rankings

AKTS Stock Data

1.03B
17.65M
Biotechnology
Telephone & Telegraph Apparatus
Link
United States
HUNTERSVILLE

AKTS RSS Feed